- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03499366
European Paediatric AFM Associated With EV-D68 Follow-up Study.
A Clinical Observational Follow-up Study of European Pediatric Cases of Acute Flaccid Myelitis Associated With EV-D68 Infection.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Title: Clinical observational follow-up study of children with Acute Flaccid Myelitis associated with EV-D68 infection- a cross European collaboration.
Study objectives: To study the clinical outcome and function of patients with Acute Flaccid Myelitis associated with enterovirus (EV)-D68 infection after 1 to 3 years, in order to assist clinicians in providing prognoses for patients and to guide further investigation.
Primary objective will be:
• Functional assessment using the Hammersmith Functional Motor Scale (HFMS) -score at follow up; 1, 2 and three years depending on time of debut
Secondary objectives are to describe these secondary outcomes and their changes over time, from onset to 1, 2 and 3 years, depending on time of debut:
- Medical Research Council (MRC) sum score at acute illness and at 1, 2 and 3 years follow up depending on time of debut as well as possible improvements over time
- MRC score in the most affected joint at acute illness and at 1, 2 and 3 years follow up depending on time of debut, as well as possible improvements over time ACTIVLIM functional score at 1, 2 and 3 years follow up depending on time of debut
- Quality of life at 1, 2 and 3 years follow up depending on time of onset measured using the Paediatric Quality of Life Inventory (PedsQL) 4.0.
- Number of days needing intensive care (range and mean)
- Number of days needing mechanical ventilation (range and mean)
- Number of deaths will be reported
- Number of complete recoveries will be reported
Explorative objectives:
- Exploring demographic parameters and how it relates to outcome (HFMS/ MRC-score/ ACTIVLIM/ PedsQL 4.0)
- Exploring different treatments and how it relates to outcome (HFMS/ MRC-score/ ACTIVLIM/ PedsQL 4.0)
- Exploring different clinical parameters and how it relates to outcome (HFMS/ MRC-score/ ACTIVLIM/ PedsQL 4.0)
- Exploring time aspects of the recovery process (individual MRC-score and MRC sum score changes).
- Characteristics on MRI will be explored with regards to outcome measures (HFMS/ MRC-score/ ACTIVLIM/ PedsQL 4.0)
- In cases with repeated MRI scans, changes will be described
- In cases with repeated neurophysiological examinations, changes will be described.
Clinical study/intervention design: This is a clinical observational study aiming at including all registered European AFM-EVD68 patients less than 18 years of age.
Safety endpoints: There is no treatment given in this study. If we become aware of important safety issues concerning included patient's treatment regimens or supportive treatment the responsible treating physician well be informed promptly via e-mail.
Duration of study: The study is intended to produce follow up data every year for two years. Inclusion will begin in March 2018 and the study terminates in March 2020. Analysis of data might hereafter continue for one year.
Follow-up: The study is a follow up study itself. Follow up will be done as close to 1 year after onset as possible and hereafter every year for minimal 2 years.
The study is intended as a clinical follow-up study exploring the outcome of patients with acute flaccid paresis associated with enterovirus D68. The patients will undergo a standard neurologic examination and assessment using Hammersmith functional motor scale expanded. The parents/ child will be asked to fill out a form concerning quality of life and activity of daily living. There will be no painful or invasive procedures and the duration of each visit can be expected to be approx. 4 hours.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Anette Ramm-Pettersen, MD, PhD
- Phone Number: 0047 23070000
- Email: arammpet@ous-hf.no
Study Locations
-
-
-
Oslo, Norway
- Recruiting
- Oslo University Hospital
-
Contact:
- Helle CV Pfeiffer, MD. PhD
- Phone Number: +47 23076182
- Email: helvie@ous-hf.no
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Acute flaccid paresis (AFP) at onset, and
- Enterovirus D-68 polymerase chain reaction (PCR) positive in any specimen in a timely sample (+/- 3 weeks from onset of paresis), and
- Age <18 years at onset, and
- Magnetic resonance imaging (MRI) of spine and brain at onset with signs of myelitis.
Exclusion Criteria:
- Major trauma
- central nervous system (CNS) malignancy
- Bleeding or infarctions in CNS
- Previous demyelinating disease
- Other infections cause of myelitis is more likely
- Patient and/or legal guardian is not able/willing to sign the consent form
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total Hammersmith Functional Motor scale- score at follow-up
Time Frame: 1 year
|
O'Hagen, J. M., et al. (2007). "An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patients." Neuromuscul Disord 17(9-10): 693-697.Neurol. 2003;7(4):155-9. The scale is a 33 items evaluation (0, 1 or 2 points in each item) and results in an overall functional score. Range: 0-66, with a higher score reflecting better performance. No sub-scores will be used. |
1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Anette ramm-Pettersen, MD, PhD, head of department
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2017/2123
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Flaccid Hemiplegia
-
Purdue UniversityCompletedFlaccid Muscle ToneUnited States
-
University of SalamancaCompleted
-
University Hospital, Clermont-FerrandUniversité d'AuvergneCompletedInfantile HemiplegiaFrance
-
Konya Beyhekim Training and Research HospitalNot yet recruiting
-
University of Castilla-La ManchaCompleted
-
University Hospital of Mont-GodinneUniversité Catholique de LouvainUnknownBimanual Training in Children With Hemiplegia With Lower Limb and Postural Stimulation (HABIT & Leg)Congenital HemiplegiaBelgium
-
Hospices Civils de LyonRecruitingAlternating HemiplegiaFrance
-
Hospices Civils de LyonCompletedAlternating HemiplegiaFrance
-
CEU San Pablo UniversityRecruiting
-
University of UtahJazz Pharmaceuticals; Alternating Hemiplegia of Childhood FoundationCompletedAlternating Hemiplegia of ChildhoodUnited States
Clinical Trials on HFMS, MRC, ACTIVLIM, PedsQl-4.0
-
Beijing Tiantan HospitalRecruitingQuality of LifeChina
-
Assistance Publique - Hôpitaux de ParisCompletedGrowth Hormone TreatmentFrance
-
University Hospital, MontpellierPediatric and Congenital Cardiology Department of Necker-enfant malades University...CompletedQuality of Life Assessment of Children With Congenital Heart Disease Aged 5 to 7 Years (QoL-CHD-5-7)Congenital Heart DiseaseFrance